These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction. Piccini JP; Schulte PJ; Pieper KS; Mehta RH; White HD; Van de Werf F; Ardissino D; Califf RM; Granger CB; Ohman EM; Alexander JH Crit Care Med; 2011 Jan; 39(1):78-83. PubMed ID: 20959785 [TBL] [Abstract][Full Text] [Related]
9. Report from J-PULSE multicenter registry of patients with shock-resistant out-of-hospital cardiac arrest treated with nifekalant hydrochloride. Yasuda S; Sawano H; Hazui H; Ukai I; Yokoyama H; Ohashi J; Sase K; Kada A; Nonogi H; Circ J; 2010 Nov; 74(11):2308-13. PubMed ID: 20877128 [TBL] [Abstract][Full Text] [Related]
10. [Treatment for perioperative arrhythmias with nifekalant hydrochloride]. Nishida M; Okada H; Murakami M; Hamano K Kyobu Geka; 2006 Mar; 59(3):210-3. PubMed ID: 16528993 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and proarrhythmia with the use of d,l-sotalol for sustained ventricular tachyarrhythmias. Kühlkamp V; Mermi J; Mewis C; Seipel L J Cardiovasc Pharmacol; 1997 Mar; 29(3):373-81. PubMed ID: 9125676 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of nifekalant hydrochloride in the treatment of fatal ventricular arrhythmia in patients with ischemic heart disease. Ando J; Kakishita M; Sakai K; Komura Y; Nishiyama K; Iwabuchi M; Yokoi H; Yasumoto H; Nosaka H; Nobuyoshi M Int Heart J; 2005 Jul; 46(4):647-56. PubMed ID: 16157956 [TBL] [Abstract][Full Text] [Related]
13. Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent. Singh BN Am J Cardiol; 1996 Aug; 78(4A):41-53. PubMed ID: 8780328 [TBL] [Abstract][Full Text] [Related]
14. An overview of antiarrhythmic drug management of electrical storm. Kowey PR Can J Cardiol; 1996 Apr; 12 Suppl B():3B-8B; discussion 27B-28B. PubMed ID: 8616726 [TBL] [Abstract][Full Text] [Related]
15. Intravenous lidocaine versus intravenous amiodarone (in a new aqueous formulation) for incessant ventricular tachycardia. Somberg JC; Bailin SJ; Haffajee CI; Paladino WP; Kerin NZ; Bridges D; Timar S; Molnar J; Am J Cardiol; 2002 Oct; 90(8):853-9. PubMed ID: 12372573 [TBL] [Abstract][Full Text] [Related]
16. Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment. Kühlkamp V; Mewis C; Mermi J; Bosch RF; Seipel L J Am Coll Cardiol; 1999 Jan; 33(1):46-52. PubMed ID: 9935007 [TBL] [Abstract][Full Text] [Related]
17. Comparison of electrophysiologic effects of intravenous E-4031 and MS-551, novel class III antiarrhythmic agents, in patients with ventricular tachyarrhythmias. Naitoh N; Tagawa M; Yamaura M; Taneda K; Furushima H; Aizawa Y Jpn Heart J; 1998 Jul; 39(4):457-67. PubMed ID: 9810296 [TBL] [Abstract][Full Text] [Related]
18. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs). Lu HR; Yan GX; Gallacher DJ J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247 [TBL] [Abstract][Full Text] [Related]
19. [Torsades de pointes ventricular tachycardia induced by intravenous amiodarone]. Makai A; Rudas L; Liszkai G; Fazekas T Orv Hetil; 2003 Feb; 144(5):241-7. PubMed ID: 12647553 [TBL] [Abstract][Full Text] [Related]
20. Effect of nifekalant for acute conversion of atrial flutter: the possible termination mechanism of typical atrial flutter. Morita N; Tanaka K; Yodogawa K; Hayashi M; Akutsu K; Yamamoto T; Satoh N; Kobayashi Y; Katoh T; Takano T Pacing Clin Electrophysiol; 2007 Oct; 30(10):1242-53. PubMed ID: 17897127 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]